-
1Academic Journal
Συγγραφείς: T. V. Bauer, T. V. Tregubchak, S. N. Shchelkunov, R. A. Maksyutov, E. V. Gavrilova, Т. В. Бауэр, Т. В. Трегубчак, С. Н. Щелкунов, Р. А. Максютов, Е. В. Гаврилова
Συνεισφορές: Работа выполнена при финансовой поддержке Российского научного фонда (проект № 1615-10101)
Πηγή: Medical Immunology (Russia); Том 22, № 2 (2020); 371-378 ; Медицинская иммунология; Том 22, № 2 (2020); 371-378 ; 2313-741X ; 1563-0625
Θεματικοί όροι: гранулоцитарно-макрофагальный колониестимулирующий фактор, extracellular envelope form, cancer, oncolytic virus, immunotherapy, granulocyte-macrophage colony-stimulating factor, внеклеточные оболочечные формы вируса, рак, онколитический вирус, иммунотерапия
Περιγραφή αρχείου: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/1594/1244; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3943; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3944; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3945; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3947; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3948; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3949; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3950; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3951; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3952; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3953; https://www.mimmun.ru/mimmun/article/downloadSuppFile/1594/3954; Autio K., Knuuttila A., Kipar A., Pesonen S., Guse K., Parviainen S., Rajamaki M., Laitinen-Vapaavuori O., Vaha-Koskela M., Kanerva A., Hemminki A. Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles. Mol. Ther. Oncolytics, 2014, Vol. 1, 14002. doi:10.1038/mto.2014.2.; Blasco R., Sisler J. R., Moss B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. Virol., 1993, Vol. 67, no. 6, pp. 3319-3325.; Bourke M.G., Salwa S., Harrington K.J., Kucharczyk M.J., Forde P.F., de Kruijf M., Soden D., Tangney M., Collins J.K., O’Sullivan G.C. The emerging role of viruses in the treatment of solid tumours. Cancer Treat. Rev., 2011, Vol. 37, no. 8, pp. 618-632.; Buller R.M., Smith G.L., Cremer K., Notkins A.L., Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature, 1985, Vol. 317, no. 6040, pp. 813-815.; Burnette W.N. “Western blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulpatepolyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem., 1981, Vol. 112, no. 2, pp. 195-203.; Cush S.S., Reynoso G.V., Kamenyeva O., Bennink J.R., Yewdell J.W., Hickman H.D. Locally produced IL-10 limits cutaneous vaccinia virus spread. PLoS Pathog., 2016, Vol. 12. no. 3, e1005493. doi:10.1371/journal.ppat.1005493.; de Vries C.R., Monken C.E., Lattime E.C. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia - GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther., 2015, Vol. 22, no. 3, pp. 154-162.; di Tucci C., Schiavi M.C., Faiano P, d’Oria O., Prata G., Sciuga V, Giannini A., Palaia I., Muzii L., Benedetti Panici P Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. Crit. Rev. Oncol. Hematol., 2018, Vol. 128, pp. 30-42.; Dranoff G., Jaffee E., Lazenby A., Golumbek P, Levitsky H., Brose K., Jackson V, Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, no. 8, pp. 3539-3543.; Falkner F.G., Moss B. Transient dominant selection of recombinant vaccinia viruses. J. Virol., 1990, Vol. 64, no. 6, pp. 3108-3111.; Goncharova E.P., Ruzhenkova J.S., Petrov I.S., Shchelkunov S.N., Zenkova M.A. Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. J. Transl. Med., 2016, Vol. 14, no. 1, 241. doi:10.1186/s12967-016-1002-x.; Gopalakrishnan V, Helmink B.A., Spencer C.N., Reuben A., Wargo J.A. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell, 2018, Vol. 33, no. 4, pp. 570-580.; Maksyutov R.A., Tregubchak T.V., Denisova N.I., Maksyutov A.Z., Gavrilova E.V Gene-armed oncolytic poxvirus against cancer. Acad. J. Cancer Res., 2013, Vol. 6, no. 1, pp. 45-49.; Russell L., Peng K.W The emerging role of oncolytic virus therapy against cancer. Chin. Clin. Oncol., 2018, Vol. 7, no. 2, p. 16.; Russell S.J., Peng K.W, Bell J.C. Oncolytic virotherapy. Nat. Biotechnol., 2012, Vol. 30, no. 7, pp. 658-670.; Smith G.L., Vanderplasschen A., Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol., 2002, Vol. 83, no. 12, pp. 2915-2931.; Tim Martin N., Cameron Bell J. Oncolytic virus combination therapy: Killing one bird with two stones. Mol. Ther., 2018, Vol. 26, no. 6, pp. 1414-1422.; Vaha-Koskela M.J., Heikkila J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett., 2007, Vol. 254, no. 2, pp. 178-216.; https://www.mimmun.ru/mimmun/article/view/1594